Avonex (interferon beta-1a) Coverage Criteria
Customize your policy alerts
Sign up for Oscar Health Policy PG218 alerts
Get alerted when Policy PG218 changes without checking for updates manually.
Monitor payer policy activity
This guideline governs prior authorization and medical necessity review for Avonex (interferon beta-1a) for pediatric and adult members with multiple sclerosis or clinically isolated syndrome. It defines initial and continuation criteria, quantity limits, documentation requirements, and non-covered uses.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.